Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics

Condition(s) targeted: Diabetes Mellitus, Type 2

Intervention: insulin detemir (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Novo Nordisk

Official(s) and/or principal investigator(s):
Karel Rychna, MD, Study Director, Affiliation: Novo Nordisk s.r.o.
Dana Raabova, MD, Study Director, Affiliation: Novo Nordisk s.r.o.

Overall contact:
Public Access to Clinical Trials - Novo Nordisk, Phone: Please Contact NN via email, Email: clinicaltrials@novonordisk.com

This study is conducted in Europe.

Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins

Official title: Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir®) in Type 2 Patients, Previously Treated With Other Basal Insulins

Study design: Cohort, Prospective

Primary outcome: weight effect

Secondary outcome:

Improvement in FPG levels

Improvement in HbA1c levels

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Type 2 diabetes

- Current treatment with insulin NPH or glargine

- The selection of the subjects will be at the discretion of the individual physician

Exclusion Criteria:

- Current treatment with insulin detemir

- Previous enrolment in this study

- Hypersensitivity to insulin detemir or to any of the excipients.

- Women who are pregnant, breast feeding or have the intention of becoming pregnant

within next 12 months

Public Access to Clinical Trials - Novo Nordisk, Phone: Please Contact NN via email, Email: clinicaltrials@novonordisk.com

Prague 16000, Czech Republic; Recruiting

Clinical Trials at Novo Nordisk

Starting date: May 2008
Ending date: September 2009
Last updated: September 16, 2008